BACKGROUND: Current glioma grading schemes are limited by subjective histological criteria. Imidazoline I(2) receptors are principally expressed on glial cells. OBJECTIVE: To investigate the feasibility of using the measurement of imidazoline I(2) receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas. METHODS: The specific binding of [(3)H]idazoxan to imidazoline I(2) receptors was measured in homogenates from human gliomas of different grades. RESULTS: The density of imidazoline I(2) receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours. The increase in density correlated with the malignancy grade of the gliomas. No significant differences in affinity values were observed. CONCLUSION: These results suggest that the density of imidazoline I(2) receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas.
BACKGROUND: Current glioma grading schemes are limited by subjective histological criteria. Imidazoline I(2) receptors are principally expressed on glial cells. OBJECTIVE: To investigate the feasibility of using the measurement of imidazoline I(2) receptor expression to differentiate glial tumours from other types of brain tumours and for grading the different gliomas. METHODS: The specific binding of [(3)H]idazoxan to imidazoline I(2) receptors was measured in homogenates from humangliomas of different grades. RESULTS: The density of imidazoline I(2) receptors was significantly greater in the three types of malignant glial tumours than in postmortem control brain or non-glial tumours. The increase in density correlated with the malignancy grade of the gliomas. No significant differences in affinity values were observed. CONCLUSION: These results suggest that the density of imidazoline I(2) receptors may be a useful radioligand parameter for the differentiation of glial tumours from other types of brain tumours and for grading the different gliomas.
Authors: Christian Griñán-Ferré; Foteini Vasilopoulou; Sònia Abás; Sergio Rodríguez-Arévalo; Andrea Bagán; Francesc X Sureda; Belén Pérez; Luis F Callado; Jesús A García-Sevilla; M Julia García-Fuster; Carmen Escolano; Mercè Pallàs Journal: Neurotherapeutics Date: 2019-04 Impact factor: 7.620
Authors: Andrea Bagán; José A Morales-García; Christian Griñán-Ferré; Caridad Díaz; José Pérez Del Palacio; Maria C Ramos; Francisca Vicente; Belén Pérez; José Brea; María Isabel Loza; Mercè Pallàs; Carmen Escolano Journal: Int J Mol Sci Date: 2022-05-12 Impact factor: 6.208
Authors: Ashwin V Venkataraman; Nicholas Keat; James F Myers; Samuel Turton; Inge Mick; Roger N Gunn; Eugenii A Rabiner; Jan Passchier; Christine A Parker; Robin J Tyacke; David J Nutt Journal: EJNMMI Res Date: 2018-07-30 Impact factor: 3.138